Stockscreener 앱 받기
2.15
0.92%
-0.02
시간 외 거래:
2.16
0.01
+0.47%
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX) - The Globe and Mail
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen - The Globe and Mail
Investment Recap: Does Black Diamond Therapeutics Inc align with a passive investing strategy2026 Setups & Weekly High Potential Alerts - baoquankhu1.vn
Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives - simplywall.st
BDTX: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) Stock - MarketBeat
Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating - marketscreener.com
Black Diamond: Fourth Quarter Financial Results Overview - Bitget
Black Diamond Therapeutics 2025 Annual Report – Clinical-Stage Oncology Pipeline, MasterKey Therapies, and Regulatory Overview - Minichart
Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials in EGFR-Related Cancers - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Releases Earnings Results - MarketBeat
Black Diamond: Q4 Earnings Snapshot - kare11.com
BDTX: Strong clinical and financial performance, with silevertinib advancing and cash runway to 2028 - TradingView
Silevertinib data and Servier pact shape Black Diamond (NASDAQ: BDTX) - Stock Titan
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[8-K] Black Diamond Therapeutics, Inc. Reports Material Event | BDTX SEC FilingForm 8-K - Stock Titan
Cancer drug hitting 60% response rate now funded into 2028 - Stock Titan
Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials i - GuruFocus
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BDTX (Black Diamond Therapeutics) NonCurrent Deferred Reven - GuruFocus
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - Finviz
Published on: 2026-03-07 03:01:03 - baoquankhu1.vn
Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference - MarketBeat
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? - MSN
Downgrade Watch: Whats the profit margin of Black Diamond Therapeutics IncWeekly Market Summary & Real-Time Stock Entry Alerts - baoquankhu1.vn
BDTX: Silevertinib demonstrates robust efficacy in NSCLC and is advancing to pivotal GBM trials - TradingView
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - Quantisnow
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - Sahm
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Clinical-stage oncology firm Black Diamond sets 3 investor events - Stock Titan
Revenue Check: Is Black Diamond Therapeutics Inc a strong growth stock2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
BDTX PE Ratio & Valuation, Is BDTX Overvalued - Intellectia AI
Hedge Fund Bets: Is Black Diamond Therapeutics Inc a strong growth stock2025 Key Highlights & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Black Diamond Therapeutics (BDTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
BDTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Will Black Diamond Therapeutics Inc. benefit from AI trendsTrade Exit Summary & High Yield Stock Recommendations - mfd.ru
Breakout Zone: What hedge funds are buying Black Diamond Therapeutics IncJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Is Black Diamond Therapeutics Inc. stock undervalued vs historical averagesTrade Entry Summary & Daily Profit Maximizing Trade Tips - mfd.ru
Dividend Watch: Does Capitol Investment Corp VI Debt Equity Composite Units align with a passive investing strategyMarket Movement Recap & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 0.5%Here's Why - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 0.5% – Here’s Why - Defense World
Dip Buying: Will Black Diamond Therapeutics Inc benefit from AI trendsJuly 2025 Technicals & Reliable Entry Point Alerts - baoquankhu1.vn
Vestal Point holds 1.5% of Black Diamond Therapeutics (BDTX) stock - Stock Titan
Portfolio Update: Is AEVAW a strong candidate for buy and holdMarket Weekly Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Does Black Diamond Therapeutics Inc. outperform in volatile marketsEarnings Summary Report & Community Consensus Stock Picks - mfd.ru
Why Black Diamond Therapeutics Inc. stock is popular among millennialsJuly 2025 Review & AI Enhanced Execution Alerts - mfd.ru
BDTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Black Diamond Therapeutics Inc. reach all time highs this year2025 Valuation Update & Weekly High Potential Stock Alerts - mfd.ru
What is Black Diamond Therapeutics Inc. s revenue forecast2025 Risk Factors & High Accuracy Buy Signal Tips - mfd.ru
Black Diamond Therapeutics, Inc. (BDTX) price target trimmed as Piper updates biotech models and 2026 catalyst tracker - MSN
Will Black Diamond Therapeutics Inc. stock sustain high P E ratiosExit Point & Daily Profit Focused Screening - mfd.ru
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker - Finviz
Dow Update: What is Black Diamond Therapeutics Incs revenue forecast2025 Biggest Moves & Daily Growth Stock Investment Tips - baoquankhu1.vn
What’s the profit margin of Black Diamond Therapeutics Inc.Take Profit & Safe Entry Zone Tips - mfd.ru
Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer - BioSpace
1.20%
0.06%
자본화:
|
볼륨(24시간):